Editorial: Measurable residual disease in hematologic malignancies
Francesco Buccisano1, Raffaele Palmieri1, Monica L Guzman2
1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Frontiers in Oncology
|May 26, 2023
Summary
No abstract available in PubMed .
Keywords:
MRD - measurable residual diseasechimerism after allo-HSCTmultiparameter flow cytometrynext generation flow cytometry (NGF)next generation sequencingpolymerase chain reactionsurrogate endpoint biomarkerMore Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.4K
